Related Experiment Video

Updated: Mar 30, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen

Barbara J Brennan1, Annabelle Lemenuel-Diot2, Eric Snoeck3

  • 1Hoffmann-La Roche Inc., Nutley, NJ, USA.

British Journal of Clinical Pharmacology
|November 4, 2015
PubMed

Insights

A simplified dosing regimen for peginterferon alfa-2a was developed for children with chronic hepatitis C. This new regimen ensures safe and effective drug exposure in pediatric patients aged 5 years and older.

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Pediatric Pharmacology
  • Hepatology

Background:

  • Chronic hepatitis C in children requires effective treatment.
  • Peginterferon alfa-2a is a key antiviral medication.
  • Optimizing pediatric dosing is crucial for treatment success.

Purpose of the Study:

  • To simplify the dosing regimen of peginterferon alfa-2a for pediatric patients.
  • To establish a dosing strategy that ensures therapeutic drug exposure in children.
  • To align pediatric dosing with established adult safety and efficacy profiles.

Main Methods:

  • A population pharmacokinetic (PK) model was developed using data from pediatric and adult patients.
  • Simulations were performed to identify a simplified dosing regimen.
  • Model predictions were validated against observed clinical data.

Main Results:

  • A two-compartment PK model was established, incorporating body surface area and weight as covariates.
  • A simplified dosing regimen was identified, providing comparable exposures to previous pediatric trials.
  • This regimen is approved for treatment-naive children and adolescents aged ≥5 years.

Conclusions:

  • Combining adult and pediatric PK data enabled robust model development.
  • The developed PK model accurately predicted drug exposure in both populations.
  • This facilitated the creation of a simplified and effective peginterferon alfa-2a dosing regimen for pediatric patients.
Abstract

Keywords:
chronic hepatitis Cmodelling and simulationpaediatric dosing regimenpegIFN alfa-2apharmacokinetics

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

8.0K

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
466
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
71
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
255
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257